nutropinaq 10mg2ml solution for injection cartridges
ipsen ltd - somatropin (rbe) - solution for injection - 5mg/1ml
increlex 40mg4ml solution for injection vials
ipsen ltd - mecasermin - solution for injection - 10mg/1ml
cabometyx 20mg tablets
ipsen ltd - cabozantinib s-malate - tablet - 20mg
cabometyx 40mg tablets
ipsen ltd - cabozantinib s-malate - tablet - 40mg
cabometyx 60mg tablets
ipsen ltd - cabozantinib s-malate - tablet - 60mg
somatuline la 30mg powder and solvent for suspension for injection vials
ipsen ltd - lanreotide acetate - powder and solvent for suspension for injection - 30mg
reclipsen 28 day- desogestrel and ethinyl estradiol kit
teva pharmaceuticals usa, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.15 mg - reclipsen™ (desogestrel and ethinyl estradiol tablets usp) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with reclipsen (desogestrel and ethinyl estradiol tablets usp), 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. table 1: percentage of women experiencing an unintended pregnancy during the first year of typi
reclipsen 28 day- desogestrel and ethinyl estradiol kit
rpk pharmaceuticals, inc. - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - reclipsen™ (desogestrel and ethinyl estradiol tablets usp) is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system depends upon the reliability with which they are used. correct and consistent use of these methods can result in lower failure rates. in a clinical trial with reclipsen (desogestrel and ethinyl estradiol tablets usp), 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. this represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. this rate includes patients who did not take the drug correctly. table 1: percentage of women experiencing an unintended pregnancy during the first year of typi
dysport for injection 500 uvial
ipsen pharma singapore pte. ltd. - clostridium botulinum type a toxin-haemagglutinin complex - injection, powder, for solution - 500 u/vial - clostridium botulinum type a toxin-haemagglutinin complex 500 u/vial
diphereline p.r. powder and solvent for suspension for injection 11.25 mgvial
ipsen pharma singapore pte. ltd. - triptorelin pamoate eqv. triptorelin - injection, powder, for suspension, extended release - 11.25 mg/vial - triptorelin pamoate eqv. triptorelin 11.25 mg/vial